Indonesia clinical laboratory market segment (by type of clinical laboratory, by type of private independent laboratory, by type of customer, by payer, by type of test and by region), competitive landscape of major players in Indonesia clinical laboratory market, and covering company profile of major clinical labs including Prodia, Kimia Farma Diagnostika, Pramita, Cito, BioMedika and Parahita. The report concludes with market projection for future and analyst recommendations highlighting the major opportunities and cautions.
- The healthcare market in Indonesia was majorly impacted by the implementation of JKN (Indonesian National Health Insurance) as the demand for affordable/primary healthcare services, laboratory services, and generic medicines increased.
- The private independent clinical laboratory market is dominated by organized laboratory chains. Prodia is the market leader in Indonesia Clinical Laboratory Market supported by the largest labs network and experienced management team.
Indonesia Healthcare market will be facilitated by the rising number of healthcare providers coupled with elevating prevalence of chronic diseases such as diabetes, HIV, Tuberculosis and others. More than 35,000 new beds are likely to be added in Indonesia by 2020.
The clinical laboratory market is expected to increase 1.5 times by 2022 supported by higher growth in esoteric tests segment. The esoteric tests segment is expected to register a high growth during this period. The standardization of the Coordination of Benefits (CoB) agreement between private insurers and JKN will create opportunities for private independent laboratories to collaboration with private hospitals resulting in increase in external referrals. Private hospitals without facilities to perform specialized or esoteric tests will be able to refer out these tests to private independent laboratories for those patients who require these tests and are covered through the CoB scheme. The major private independent laboratories chains are expected to undergo geographic expansion beyond key cities into underdeveloped areas. This will further lead to increase in market share in the overall Indonesia clinical laboratory market. For instance Prodia plans to establish up to 33 new clinical laboratories by 2021. Further, the industry will witness a rising trend towards precision medicine also known as personalized medicine. Growth in the availability of testing equipment that can be operated locally and that does not require free-standing clinical laboratories and advancements in self-testing kits that can be operated by customers themselves can result in a decrease in the volume of tests at laboratories.
Rising awareness of preventive healthcare supported by growing disposable income coupled with elevating prevalence of chronic and lifestyle diseases will lead to an increase in number of walk-in patients which will propel Indonesia clinical laboratory market revenue in future.
Ken Research in its latest study, “Indonesia Clinical Laboratory Market Outlook to 2022 – By Type (Public Clinical Lab, Private Hospital Labs and Private Independent Labs), By Type of Test (Routine, Non Laboratory and Esoteric)”, suggests that clinical laboratory market is expected to reach USD 3.2 billion by 2022 growing at a CAGR of 11.5%.
For more information on the research report, refer to below link:
Related Reports by Ken Research
Ankur Gupta, Head Marketing & Communications